Sessions are scheduled in local time (CEST)
Berlin Hall
Educational session
Date
Thu, 11.05.2023
Time
16:45 - 18:15
Room
Berlin Hall
Chairs
- Heather L. McArthur (Dallas, United States of America)
HER2 and beyond: The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers (ID 6)
Clinical impact of evolving ADC technology (ID 17)
Lecture Time
16:45 - 17:05
Session Name
Room
Berlin Hall
Date
Thu, 11.05.2023
Time
16:45 - 18:15
Speakers
- Heather L. McArthur (Dallas, United States of America)
HER2 and beyond: The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers (ID 6)
Current ADC landscape (ID 18)
Lecture Time
17:05 - 17:25
Session Name
Room
Berlin Hall
Date
Thu, 11.05.2023
Time
16:45 - 18:15
Speakers
- Veronique C. Dieras (Rennes, France)
HER2 and beyond: The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers (ID 6)
Emerging toxicities and management strategies (ID 19)
Lecture Time
17:25 - 17:45
Session Name
Room
Berlin Hall
Date
Thu, 11.05.2023
Time
16:45 - 18:15
Speakers
- Sung-Bae Kim (Seoul, Korea, Republic of)
HER2 and beyond: The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers (ID 6)
Future directions for ADCs (ID 20)
Lecture Time
17:45 - 18:05
Session Name
Room
Berlin Hall
Date
Thu, 11.05.2023
Time
16:45 - 18:15
Speakers
- Javier Cortés (Madrid, Spain)
HER2 and beyond: The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers (ID 6)
Q&A and discussion (ID 74)
Lecture Time
18:05 - 18:15
Session Name
Room
Berlin Hall
Date
Thu, 11.05.2023
Time
16:45 - 18:15